Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Halma Plc LSE:HLMA London Ordinary Share GB0004052071 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  14.00 0.68% 2,060.00 2,059.00 2,061.00 2,062.00 1,989.50 2,006.00 1,495,522 16:29:59
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 1,525.3 304.4 64.5 31.9 7,811

Halma Share Discussion Threads

Showing 326 to 350 of 575 messages
Chat Pages: 23  22  21  20  19  18  17  16  15  14  13  12  Older
DateSubjectAuthorDiscuss
07/2/2013
17:04
GL Apad I topped up back in August,probably for a final time, will wait to find out more about the acquisiations before deciding though. Such a good strong company cant really see anything negative in the fundamentals.
buster78
07/2/2013
11:22
Increased HLMA today.
apad
23/1/2013
09:48
Halma, the leading safety, health and environmental technology group announces the completion on 23 January 2013 of the acquisition of Thinketron Precision Equipment Company Limited ('TPE') based in Hong Kong and its subsidiaries Baoding Longer Precision Pump Co., Ltd ('Longer Pump') based in China and Langer Instruments Corporation ('LIC') based in the USA. Longer Pump manufactures and markets peristaltic, syringe and gear pumps used in laboratory, medical and industrial applications. LIC is Longer Pump's distributor in the USA. The initial cash consideration was RMB 237 million (GBP23.7 million) for the share capital of TPE. Deferred consideration of RMB 3 million (GBP0.3 million), which is adjustable RMB for RMB if the net tangible asset value (NTAV) is over/under a targeted amount, is payable upon agreement of the NTAV. The targeted NTAV includes approximately RMB 22.5 million (GBP2.25 million) of cash. Unaudited accounts for the year ended 31 December 2012 show adjusted operating profit of RMB 23.5 million (GBP2.35 million). Audited accounts for the year ended 31 December 2011 show adjusted operating profit of RMB 18.2 million (GBP1.82 million). Existing management of Longer Pump and LIC will remain in place and will continue to operate the business supported by new Board members appointed from within Halma China. The acquisition, which is expected to be immediately earnings enhancing, has been funded from Halma's cash and debt facilities. Longer Pump will join Halma's Health & Analysis sector within the Fluid Technology sub-sector adding complementary high-value fluid handling products which are sold through a large sales network in China. Approximately 80% of Longer Pump's revenue is generated from China. Andrew Williams, Halma's Chief Executive, commented: "Longer Pump's alignment with Halma's growth drivers is strong. Sales of their products are driven by increasing demand for healthcare and healthcare research, as well as the urbanisation and industrialisation within China. Their significant local market knowledge and technical resources will help our Fluid Technology sub-sector accelerate growth in this important region. There are also opportunities for Halma to contribute to the growth of Longer Pump, utilising both the network of regional hub offices which Halma has established within China and the worldwide reach of our Fluid Technology businesses."
bluebelle
22/11/2012
11:55
Nope apart from valuation. Added a few on the results.
wjccghcc
22/11/2012
10:45
Been through the interims looking for negatives and can't find any. Half year to half year doesn't throw up any inconsistencies I can find. Without the acquisitions and disposal their debt would have dropped significantly. On this basis I have marked HLMA as an "increase" for my portfolio. Anyone found any negatives? apad
apad
20/11/2012
08:34
Adjusted pre-tax profit from continuing operations1 up 6% to £60.8m (2011/12: £57.5m) on revenue up 6% at £298.1m (2011/12: £280.0m). Organic growth2 at constant currency: Profit up 3%, Revenue up 3%. Strong growth in Asia Pacific and Australasia with revenue up 17% including 32% growth in China. Good overall revenue performance in developed regions, with USA up 19% offsetting weaker demand in UK and Europe. Health and Analysis and Industrial Safety Sectors performed strongly with double-digit profit growth. Infrastructure Sensors profit marginally lower - Elevator Safety reorganisation completed on schedule. High level of returns maintained: Return on Sales3 of 20.4% (2011/12: 20.5%), Return on Total Invested Capital of 16.4% (2011/12: 16.9%) and Return on Capital Employed of 71.6% (2011/12: 68.8%). Three acquisitions and one disposal completed during the period, acquisition pipeline remains healthy. Adjusted earnings per share from continuing operations4 up 5% to 12.34p (2011/12: 11.75p). Statutory earnings per share up 25% to 13.14p (2011/12: 10.52p). Interim dividend of 4.06p per share, up 7% (2011/12: 3.79p). Net debt of £74m at period end (March 2012: £19m). Borrowing facilities of £260m in place until 2016, providing significant financial capacity for further organic growth and value adding acquisitions. Andrew Williams, Chief Executive of Halma, commented: "Halma made good progress during the period, achieving record revenue and profit and strong returns. Our focus on building strong positions in markets with sustainable, long-term growth drivers such as Health and Safety regulation, increasing demand for healthcare and the need for life-critical resources (including energy and water) is providing both resilience and opportunities to grow. Order intake continues to be slightly ahead of revenue and Halma remains on track to make further progress in the second half of the year."
bluebelle
12/11/2012
15:03
Halma plc will be announcing its Half Year Results and the interim dividend for the 26 weeks ended 29 September 2012 on Tuesday, 20 November 2012.
bluebelle
20/9/2012
17:24
What has caused the rise today, I wonder. Anyone noticed any news?
jodi17qad
20/9/2012
16:50
As I've often said before, some of the best stocks have the quietest bbs.
bluebelle
13/8/2012
19:29
From the AGM statement.
essentialinvestor
13/8/2012
19:23
EI, The 2% figure was in the last rns. Is your 2% from somewhere different? apad
apad
13/8/2012
11:47
It's not so much a comment on HLMA btw, I use it as an indicator of how tough the global economy is -- as Halma choose high growth markets and choose these very carefully.
essentialinvestor
13/8/2012
10:57
agree, out at the moment.
elmfield
13/8/2012
10:55
Fully priced at these levels EI. apad
apad
13/8/2012
08:46
Organic growth of 2% on the latest update, may indicate how quickly the global economy is now slowing imv.
essentialinvestor
24/7/2012
17:50
another good trading update. i don't see anything to concern me near term
cnx
23/6/2012
08:36
EI Operating Cash Flow year on year is more or less constant. However, 2nd half increase is significant (60 cf 45). This has offset the first half drop (36 cf 49). apad
apad
15/6/2012
11:48
ADAP, any further thoughts on the HLMA cashflow at the finals appreciated, cash generation looks to have been far stronger on the full year look than at the interim stage - unless I am misreading this.
essentialinvestor
15/6/2012
11:03
Yes, I'm surprised the dividend performance hasn't attracted more attention - I've certainly appreciated it over the years !
bluebelle
14/6/2012
07:48
"the 33rd consecutive year of dividend increases of 5% or more." The usual solid performance that we have become accustomed to.
colino bambino
14/6/2012
07:16
HALMA plc PRELIMINARY RESULTS FOR THE 52 WEEKS TO 31 MARCH 2012 14 JUNE 2012 Record results and continued dividend growth Halma, the leading safety, health and environmental technology group, today announces its preliminary results for the 52 weeks to 31 March 2012. Highlights include: -- Pre-tax profit(1) from continuing operations up 15% to GBP120.5m (2011: GBP104.6m) on revenue up 12% at GBP579.9m (2011: GBP518.4m). -- Organic growth(2) at constant currency: Profit up 5%, Revenue up 6%. -- High and increased level of returns achieved, Return on Sales(3) of 20.8% (2011: 20.2%), Return on Total Invested Capital(2) of 16.8% (2011: 15.5%) and Return on Capital Employed(2) of 74.7% (2011: 71.9%). -- Strong revenue growth in developed regions, with UK up 18%, Europe up 12% and US up 8%. Revenue from markets in the rest of the world up 11% including 25% growth in China. -- All three sectors reported increased revenue and profit, with particularly strong performances in Health and Analysis and Industrial Safety. -- Adjusted earnings per share(4) from continuing operations up 19% to 24.46p (2011: 20.49p). Statutory earnings per share up 20% to 23.01p (2011: 19.23p). -- A final dividend of 5.95p per share, making a record total dividend of 9.74p per share for the year. The increase of 7% marks the 33rd consecutive year of dividend increases of 5% or more. -- Two acquisitions and one disposal completed during the year with three further acquisitions completed since the year end. -- Good cash generation resulting in year-end net debt of GBP18.7m (2011: GBP37.1m). Strong balance sheet with borrowing facilities of GBP260m in place until 2016 providing significant financial capacity for further organic growth and value adding acquisitions. Andrew Williams, Chief Executive of Halma, commented: "Our focus on safety, health and environmental technology is continuing to provide opportunities for growth in both developed and developing regions. The combination of strong local operational management and active portfolio management ensures that we are able to deliver short-term financial performance and invest for growth in the longer term. These qualities are reflected in this year's performance and in Halma's track record of growth and high returns over a long period. We expect to continue to make progress in the year ahead."
bluebelle
31/5/2012
09:53
Good move, IMHO. I like acquisitions which are bang on the core strategy, which this clearly is. Halma plc ('Halma') ACQUISITION Halma, the leading safety, health and sensor technology group, today announces the acquisition of SunTech Medical Group Limited ("SunTech") on 31 May 2012. SunTech (www.suntechmed.com) is a pre-eminent supplier of clinical grade non-invasive blood pressure monitoring products and technologies. They sell both under the SunTech brand and through a variety of medical device OEMs which incorporate SunTech products into their own patient monitoring systems. The company manufactures at its headquarters in Morrisville, North Carolina, USA and in Shenzhen, China with a sales office in Eynsham, UK. The initial cash consideration is $46.0 million (GBP29.7 million) for the share capital plus $5.0 million (GBP3.2 million) for cash retained in the business. The combined consideration is adjustable Dollar for Dollar based on the level of working capital and cash at closing. Working capital, excluding cash, is expected to be approximately $8.3 million (GBP5.4 million). Contingent consideration of up to $6.0 million (GBP3.9 million) is payable if earnings for the year to December 2012 exceed a pre-determined target. Unaudited accounts, adjusted for non-recurring expenses, for the financial year ended 31 December 2011 show revenues of $23.0 million (GBP14.8 million) and an operating profit of $5.4 million (GBP3.5 million). Current trading remains good. SunTech is being acquired from management and a group of private shareholders including small private institutions and trusts. Existing management will remain in place and will continue to operate the business. The acquisition, which is expected to be immediately earnings enhancing, has been funded from Halma's cash and debt facilities. SunTech will join Halma's Health and Analysis sector within the Health Optics sub-sector which includes Riester, Keeler, Volk and Accutome. SunTech is particularly complementary to Riester, which already sells blood pressure and vital signs monitors in over 50 countries worldwide. Andrew Williams, Halma's Chief Executive, commented: "The acquisition of SunTech continues our strategy of building strong positions in markets with resilient long-term growth drivers. Their blood pressure monitoring technology is a perfect complement to Riester's own clinical grade blood pressure monitoring devices and this acquisition allows the two companies to work together to further develop their markets and products.
bluebelle
21/5/2012
18:51
elmfield yours 203 looks like you got the timing right
cnx
14/5/2012
20:11
This has held up quite well, still sitting out, no rush to get in again.
elmfield
28/3/2012
11:26
I am selling out of quite a few things and waiting over the summer to see how things go, feel market is ahead of itself, but hey what do I know! early summer so not sell in may, sell in april and go away till after the olympic farce.
elmfield
Chat Pages: 23  22  21  20  19  18  17  16  15  14  13  12  Older
ADVFN Advertorial
Your Recent History
LSE
HLMA
Halma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220928 16:55:01